Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Armstrong

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Medicinal Chemistry|August 20, 2004
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancerThorsten K Oost, Chaohong Sun, Robert C Armstrong, et al.
Journal of Medicinal Chemistry|March 3, 2012
Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic indexGang Liu, Sunny Abraham, Lan Tran, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2011
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitorsMark W Holladay, Brian T Campbell, Martin W Rowbottom, et al.
Molecular Cancer Therapeutics|February 10, 2012
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activityJoyce James, Bruce Ruggeri, Robert C Armstrong, et al.
Journal of Medicinal Chemistry|December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600EMartin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Nature|May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Medicinal Chemistry|August 20, 2004
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancerThorsten K Oost, Chaohong Sun, Robert C Armstrong, et al.
Journal of Medicinal Chemistry|March 3, 2012
Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic indexGang Liu, Sunny Abraham, Lan Tran, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2011
4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitorsMark W Holladay, Brian T Campbell, Martin W Rowbottom, et al.
Molecular Cancer Therapeutics|February 10, 2012
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activityJoyce James, Bruce Ruggeri, Robert C Armstrong, et al.
Journal of Medicinal Chemistry|December 16, 2011
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600EMartin W Rowbottom, Raffaella Faraoni, Qi Chao, et al.
Nature|May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
Pageof 3